Researchers reported Wednesday that a blood test may predict whether apparently healthy older adults are likely to develop Alzheimer’s symptoms in the next five or 10 years, turning ordinary aging into another field for medical sorting and surveillance.
Who Gets Measured
The test, which measures p-tau217, is being sold as a possible tool for speedier drug development, not as something healthy people should rush to get. The scientists behind the study said it could help identify and enroll high-risk people into studies of possible Alzheimer’s treatments or preventive strategies. That means the first real use case is not care, but recruitment into trials built around the hope that some drug, somewhere, might eventually work.
Dr. Reisa Sperling of the Mass General Brigham Neuroscience Institute, the study’s senior author, said, “Wait and get tested when you can potentially do something about it. At this point it wouldn’t change what I would tell someone to do. I’d still tell them to eat well, sleep well, exercise a lot and stay engaged.”
That advice lands with a thud beside the machinery of prediction. The test is already used to help diagnose whether people experiencing cognitive problems have Alzheimer’s or another disorder, but the new findings push it toward a broader role: sorting healthy older adults by future risk before they’ve shown symptoms.
What the Numbers Say
The Mass General Brigham team analyzed data from 2,684 older adults who were healthy when they joined long-running Alzheimer’s studies. They got the p-tau217 blood test at enrollment and yearly cognitive checkups. Between the earliest enrollment in 2004 and last year, about 478 developed cognitive impairment.
The results were stark. Symptom-free older adults who had very high levels of p-tau217 faced a 38% risk of developing cognitive impairment over five years. That risk rose to 78% by 10 years. Participants with very low p-tau217 levels had a low risk over the five- to 10-year period.
The research was published in JAMA and presented at the Alzheimer’s Association International Conference in London. It’s not clear exactly what causes Alzheimer’s, but its telltale markers are brain-clogging amyloid plaques and neuron-killing tau tangles. Sperling said the p-tau217 test measures a form of tau that correlates with how much plaque buildup someone has and gives a hint about tangles.
She said, “This is a gradual process where amyloid and tau build up in the brain and this blood-based biomarker is telling you how far you are in that process.”
What the Gatekeepers Are Saying
Scientists not involved in the study praised it, then immediately pointed to the limits. One problem is that only a small fraction of participants had been tracked for a full decade, which makes the 10-year estimate less certain than the five-year one. Another is that predictions can be clouded by other factors. Older people may die from something else, or have heart-related problems that can cause vascular dementia rather than Alzheimer’s, Drs. Suzanne Schindler of Washington University in St. Louis and David Wolk of the University of Pennsylvania wrote in a JAMA commentary.
The blood tests “are not yet precise enough to guide individualized prognosis,” Schindler and Wolk wrote. Still, they said the new work has “provided a crucial piece of the puzzle.”
That’s the language of the lab and the clinic: cautious, technical, and deeply invested in making risk legible to institutions that want to manage it. The test may be framed as reassurance or warning, but the immediate practical value described in the study is for drug development and trial enrollment, not for people trying to live their lives outside the medical pipeline.
Jessica Langbaum of the Banner Alzheimer’s Institute in Phoenix said, “We have people coming saying, ‘I want this blood test. I have a family history of Alzheimer’s disease,’” and said she strongly discourages that for now. She added that a predictive blood test would be “really important” only if ongoing studies eventually find a drug that could help people before symptoms begin.
So the promise is conditional. The test can identify people at high risk, but the system still has no clear answer for them. For now, it can name the danger, enroll the bodies, and wait for the next round of pharmaceutical hope.